Mizuho Reiterates Neutral Rating on Revance Therapeutic (RVNC)

Mizuho analyst Vamil Divan reiterated a Neutral rating and $6.66 price target on Revance Therapeutic (NASDAQ: RVNC).

The analyst commented: "RVNC traded down as low as ~17% today, due to concerns that the Revance/Crown Labs deal might fall apart, as the launch of the tender offer, expected on September 13, 2024, did not occur. Based on the company's email, we view the missed September 13th deadline to launch the tender offer as a delay and continue to expect the deal to complete. That said, we believe the absence of an explanation from the company for not launching the tender offer will likely be an overhang on the stock."

For an analyst ratings summary and ratings history on Revance Therapeutic click here. For more ratings news on Revance Therapeutic click here.

Shares of Revance Therapeutic closed at $5.97 yesterday.

You May Also Be Interested In

• Bumble Inc. (BMBL) PT Lowered to $3.20 at Citi
• Duke Energy restores 85% of Cincinnati storm outages
• L Catterton to sell $1B in Birkenstock shares in secondary offering